



MULTI-REGIONAL CLINICAL TRIALS

BIOETHICS COLLABORATIVE

MISSION

As an innovative and neutral forum, the MRCT Center Bioethics Collaborative convenes diverse stakeholders to discuss emerging issues related to the ethical conduct of global clinical research.

SPONSORS

Genentech, Inc.
Johnson & Johnson
Merck & Co., Inc.
Pfizer, Inc.
Sanofi
Takeda Pharmaceuticals U.S.A., Inc.



Identify ethical challenges through multi-stakeholder engagement



Explore strategies and discuss considerations



Craft solutions and collaborate on deliverables

OCT
2017

Recruitment of and Fair Payment to International Research Participants

JAN
2018

Enabling Informed Selection of Clinical Trials: Institution, Provider, and Participant Responsibilities

APR
2018

Return of Individual Research Results to Research Participants and Axes of Communication



Upcoming Meetings of the MRCT Center Bioethics Collaborative



JAN 22,
2019

Integrity of Clinical Trials in the Age of Social Media

Over the last decade, social media has emerged as a medium for conducting research, recruiting and engaging participants, and enabling participants to interact with each other online. The use of social media in clinical research carries many benefits, such as allowing valuable support mechanisms for participants who are often vulnerable. However, it also carries risks, including the possibility that participants may share information online in ways that permit themselves, other participants, and/or the research team to be unblinded to key aspects of the research data. At the January 22nd meeting of the Bioethics Collaborative we will further explore these risks and will work together to devise practical approaches by which investigators, sponsors, and regulatory authorities may mitigate them.



APR 16,
2019

Impact of Mobile Devices and Wearable Technologies on the Design and Conduct of Clinical Research

The widespread use of mobile smart devices and wearables has the potential to drastically change how clinical research is conceptualized and conducted. Consequently, participants' data may now be leveraged for a variety of health purposes, including the development of remote screening and diagnostic tools, early intervention programs, and the promotion of public health. While these developments can make research participation less burdensome, they also raise ethical and regulatory challenges around acceptable levels of privacy risk, necessary precautions for safeguarding participants' confidentiality, and the optimal approach to risk mitigation. Attendees of the April 16th Bioethics Collaborative will consider the role of data obtained from mobile devices in supporting FDA applications, as well as whether extra precautions are needed to safeguard the confidentiality of this data, given its nature.